Molecular Partners (OTCMKTS:MLLCF) Shares Down 9.4% – What’s Next?

Molecular Partners AG (OTCMKTS:MLLCF)’s stock price traded down 9.4% on Monday . The company traded as low as $4.53 and last traded at $4.53. 300 shares were traded during trading, a decline of 28% from the average session volume of 415 shares. The stock had previously closed at $5.00.

Molecular Partners Stock Performance

The stock’s 50-day moving average is $5.62 and its two-hundred day moving average is $5.80.

About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.